270 related articles for article (PubMed ID: 8516298)
1. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras.
Johnson MR; Look AT; DeClue JE; Valentine MB; Lowy DR
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5539-43. PubMed ID: 8516298
[TBL] [Abstract][Full Text] [Related]
2. Cell transformation by ras and regulation of its protein product.
Lowy DR; Johnson MR; DeClue JE; Cen H; Zhang K; Papageorge AG; Vass WC; Willumsen BM; Valentine MB; Look AT
Ciba Found Symp; 1993; 176():67-80; discussion 80-4. PubMed ID: 8299427
[TBL] [Abstract][Full Text] [Related]
3. Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1).
Griesser J; Kaufmann D; Eisenbarth I; Bäuerle C; Krone W
Biol Chem Hoppe Seyler; 1995 Feb; 376(2):91-101. PubMed ID: 7794530
[TBL] [Abstract][Full Text] [Related]
4. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function.
Johnson MR; DeClue JE; Felzmann S; Vass WC; Xu G; White R; Lowy DR
Mol Cell Biol; 1994 Jan; 14(1):641-5. PubMed ID: 8264632
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.
Andersen LB; Fountain JW; Gutmann DH; Tarlé SA; Glover TW; Dracopoli NC; Housman DE; Collins FS
Nat Genet; 1993 Feb; 3(2):118-21. PubMed ID: 8499944
[TBL] [Abstract][Full Text] [Related]
6. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
[TBL] [Abstract][Full Text] [Related]
7. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity.
Andersen LB; Ballester R; Marchuk DA; Chang E; Gutmann DH; Saulino AM; Camonis J; Wigler M; Collins FS
Mol Cell Biol; 1993 Jan; 13(1):487-95. PubMed ID: 8417346
[TBL] [Abstract][Full Text] [Related]
8. Contrasting levels of p21ras activation and expression of neurofibromin in peripheral primitive neuroectodermal tumour and neuroblastoma cells, and their response to retinoic acid.
Burchill SA; Berry PA; Bradbury FM; Lewis IJ
J Neurol Sci; 1998 May; 157(2):129-37. PubMed ID: 9619634
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of the neurofibromatosis type 1 protein product.
DeClue JE; Cohen BD; Lowy DR
Proc Natl Acad Sci U S A; 1991 Nov; 88(22):9914-8. PubMed ID: 1946460
[TBL] [Abstract][Full Text] [Related]
10. [Molecular genetics of neurofibromatosis type 1].
Suzuki H; Takahashi K; Shibahara S
Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
[TBL] [Abstract][Full Text] [Related]
11. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type 1 gene mutations in neuroblastoma.
The I; Murthy AE; Hannigan GE; Jacoby LB; Menon AG; Gusella JF; Bernards A
Nat Genet; 1993 Jan; 3(1):62-6. PubMed ID: 8490657
[TBL] [Abstract][Full Text] [Related]
13. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis type 1 tumour suppressor gene expression is deficient in psoriatic skin in vivo and in vitro: a potential link to increased Ras activity.
Karvonen SL; Koivunen J; Nissinen M; Ylä-Outinen H; Björkstrand AS; Peltonen J
Br J Dermatol; 2004 Feb; 150(2):211-9. PubMed ID: 14996090
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.
Nishi T; Lee PS; Oka K; Levin VA; Tanase S; Morino Y; Saya H
Oncogene; 1991 Sep; 6(9):1555-9. PubMed ID: 1923522
[TBL] [Abstract][Full Text] [Related]
16. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
Feldkamp MM; Angelov L; Guha A
Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of neurofibromin in the soft tissue tumours obtained from patients with neurofibromatosis type I.
Takahashi K; Suzuki H; Hatori M; Abe Y; Kokubun S; Sakurai M; Shibahara S
Clin Sci (Lond); 1995 May; 88(5):581-5. PubMed ID: 7614817
[TBL] [Abstract][Full Text] [Related]
19. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
Stang S; Bottorff D; Stone JC
Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
[TBL] [Abstract][Full Text] [Related]
20. Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions.
Nakafuku M; Nagamine M; Ohtoshi A; Tanaka K; Toh-e A; Kaziro Y
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6706-10. PubMed ID: 8341688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
